YS reports honoraria from PharmaEssentia Japan K.K., Novartis Pharmaceutical, and research funds under contract from Incyte Biosciences Japan and Toyo Kohan K.K. KN reports research funds from Takeda Pharmaceutical internationals. KO reports research funds under contract from PharmaEssentia Japan K.K. and Abbvie Inc. TI reports honoraria from Novartis Pharmaceutical, Sanofi, and Takeda Pharmaceutical, and honoraria and grants from Abbvie Inc. and Bristol-Myers Squibb. AG reports grants from Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., Chugai Pharmaceutical Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd., Bayer Yakuhin Ltd., Daiichi Sankyo Co. Ltd., Nihon Pharmaceutical Co. Ltd. and honoraria from Novartis Pharma K.K., Alexion Pharmaceuticals Inc., Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Daiichi Sankyo Co. Ltd., Nihon Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Sanofi K.K., and PharmaEssentia Japan K.K. MN reports research funds from Veritas Corporation and honoraria to her spouse from Amgen Inc., Astellas Pharma, AstraZeneca plc., Bristol-Myers Squibb, Daiichi Sankyo, Janssen Pharmaceutical K.K., Meiji Seika Pharma Co. Ltd., Nippon Shinyaku, Novartis Pharmaceutical, Ono Pharmaceutical, Otsuka Pharmaceutical, Sumitomo Pharma, and Takeda Pharmaceutical. FK reports grants from Takeda Pharmaceutical, Janssen Pharmaceutical K.K., Chugai Pharmaceutical, AstraZeneca K.K., AbbVie GK, Kissei Pharmaceutical, and Sanofi K.K. KK reports honoraria from Novartis Pharmaceutical, Takeda Pharmaceutical, and PharmaEssentia Japan. HW reports grants from Chugai Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical, and Takeda Pharmaceutical. KU reports research funds under contract from Astellas, Aperis, Celgene, Daichi Sankyo, MSD, Pfizer, and Yakult; honoraria under contract from Alnylam Japan and SOBI; and honoraria and research funds under contract from Novartis, Abbvie, Alexion, Amgen, Asahi Kasei Pharma, AstraZeneca, Bristol-Myers Squibb, Chugai, Eisai, Incyte, Kyowa-Kirin, Meiji Seika Pharma, Nippon-Shinyaku, Ohara, Ono, Otsuka, PharmaEssentia, Sanofi, Takeda, and Janssen. TM reports honoraria from Pfizer, Novartis Pharmaceutical, Takeda Pharmaceutical, and PharmaEssentia Japan, and research funds under contract from Asahi Kasei Pharma, Chugai Pharmaceutical, Kyowa Kirin, Eisai Pharmaceutical, JCR Pharmaceuticals, Abbvie Inc., Sumitomo Pharma, CSL Behring, Japan Blood Products Organization, and Otsuka Pharmaceutical. KS reports honoraria from Bristol-Myers Squibb, Celgene, Novartis Pharmaceutical, and Takeda Pharmaceutical; research funds under contract from PharmaEssentia Japan K.K.; and grants from Abbvie Inc., Astellas Pharma, Chugai Pharmaceutical, Kyowa Kirin, and MSD. AT reports honoraria from Takeda Pharmaceutical, research funds under contract from Kyowa Kirin, Novartis Pharmaceutical, Ono Pharmaceutical, Perseus Proteomics Inc., Pfizer, and Taiho Pharmaceutical and honoraria and research funds under contract from Chugai Pharmaceutical. YE reports research funds under contract from Meiji Seika Pharma and an endowed chair funded by PharmaEssentia Japan K.K. YH reports honoraria from Takeda Pharmaceutical and Novartis Pharmaceutical, and an endowed chair funded by PharmaEssentia Japan K.K. KA reports honoraria from Celgene and Novartis Pharmaceutical, grants from Asahi Kasei Pharma, Mochida, MSD, Mundi Pharma, Nippon Shinyaku Pharmaceutical, Ono Pharmaceutical, Shionogi, Sanofi, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Toyama Chemical, Shin Nippon Biomedical Laboratories, Yakult Honsha, and Takeda Pharmaceutical; honoraria and research funds under contract from Bristol-Myers Squibb and Janssen Pharmaceutical; honoraria and grants from Abbvie Inc., Chugai Pharmaceutical, and Eisai Pharmaceutical; research funds under contract and grants from Daiichi Sankyo and Otsuka Pharmaceutical, honoraria, research funds under contract; and grants from Astellas Pharma and Kyowa Kirin. IM received speakers bureau fees from Pfizer Japan Inc., Ono Pharmaceutical Co. Ltd., Novartis Pharma K.K., Chugai Pharmaceutical Co. Ltd., AbbVie G.K., Janssen Pharmaceutical K.K., Bristol-Myers Squibb K.K. (Celgene K.K.), AstraZeneca K.K., and Otsuka Pharmaceutical Co. Ltd. and received research funding from Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Pharma Co. Ltd., Nippon Shinyaku Co. Ltd., Eisai Co. Ltd., Asahi Kasei Pharma Corp., AbbVie G.K., Taiho Pharmaceutical Co. Ltd., and received consultancy fees from Otsuka Pharmaceutical Co. Ltd. KT reports honoraria from Novartis Pharmaceutical and MSD; grants from Astellas Pharma, Chugai Pharmaceutical, and Otsuka Pharmaceutical; and honoraria and grants from Kyowa Kirin. NK has received a salary from PharmaEssentia Japan, where he is a board member; reports honoraria from Abbvie Inc., Celgene, and Japan Tobacco Inc.; research funds under contract from FUJIFILM Wako Chemicals, Fuso-pharm, Meiji Seika Pharma, Perseus Proteomics Inc., and Pfizer, grants from Bristol-Myers Squibb, Chugai Pharmaceutical, Kyowa Kirin, and Sumitomo Dainippon Pharma; honoraria and grants from Novartis Pharmaceutical and Otsuka Pharmaceutical; and honoraria, research funds under contract, and an endowed chair funded by PharmaEssentia Japan K.K. The other authors declare no competing interests.